Stephen G. Sudovar

Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD.

AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis.

Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ.

Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada.

Part of Roche Holding AG, Roche Laboratories, Inc. markets and sells pharmaceutical medications. The company is based in Nutley, NJ.

Kessler Foundation, Inc. provides public charity and rehabilitation services. It helps the people with physical and cognitive disabilities caused by stroke, multiple sclerosis, brain and spinal cord injury, and other chronic neurologic and musculoskeletal conditions. The company is headquartered in West Orange, NJ.